Aclaris Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.15.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.54.
During the past 3 years, the average EBIT per Share Growth Rate was 22.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 12.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 13.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Aclaris Therapeutics's EBIT per Share or its related term are showing as below:
STU:8AT'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -66 Med: 12.15 Max: 23.5
Current: 22.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Aclaris Therapeutics was 23.50% per year. The lowest was -66.00% per year. And the median was 12.15% per year.
STU:8AT's 3-Year EBIT Growth Rate is ranked better than 60.36% of 1178
companies
in the Biotechnology industry
Industry Median: 15.55
vs STU:8AT: 22.70
Aclaris Therapeutics (STU:8AT) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Aclaris Therapeutics EBIT per Share Related Terms
Aclaris Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Aclaris Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.54
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aclaris Therapeutics (STU:8AT) has a EBIT per Share of €-0.54 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Aclaris Therapeutics and its competitors. According to the industry distribution chart, Aclaris Therapeutics ranks #467 out of 1178 companies in the Biotechnology industry, placing it in the top 39.6%.
Is Aclaris Therapeutics' EBIT per Share too high?
Aclaris Therapeutics' current EBIT per Share is €-0.54. Based on the distribution chart, Aclaris Therapeutics ranks #467 out of 1178 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aclaris Therapeutics has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' EBIT per Share compare to RLMD and GYRE?
According to the Biotechnology industry distribution chart, Aclaris Therapeutics ranks #467 out of 1178 companies for EBIT per Share. This puts Aclaris Therapeutics in the upper half of its industry. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Aclaris Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aclaris Therapeutics's current EBIT per Share is €-0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (STU:8AT) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.39, compared to a current price of €4.83 — trading 1139% above its estimated fair value. The current EBIT per Share is €-0.54. Aclaris Therapeutics' overall GF Score™ is 27/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Aclaris Therapeutics (STU:8AT), the current EBIT per Share is €-0.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aclaris Therapeutics (STU:8AT) Overvalued in 2026?
Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued.
The current stock price of €4.83 is trading 1139% above its estimated GF Value™ of €0.39.
GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.
Key valuation signals for STU:8AT:
EBIT per Share: €-0.54
GF Value™: €0.39 vs. price of €4.83 (1139% above fair value)
No single metric tells the full story. See the STU:8AT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
27GF Score
Get the complete analysis for STU:8AT
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:8AT has been successfully added to your 
